Cyclosporine has an important place in the treatment of plaque psoriasis. Similar to other systemically administered anti-psoriatic agents, several common adverse effects have been noted with its use. We present an overview of the most frequent and clinically relevant side effects of cyclosporine therapy, and, to refresh dermatologists' knowledge, we discuss various aspects of structural and functional nephrotoxicity; hypertension; and the occurrence squamous cell carcinoma, lymphoma, and gingival hyperplasia.
CoroasA.S., de OliveiraJ.G., MaginaS.Cyclosporine enhances salt sensitivity of body water composition as assessed by impedance among psoriatic patients with normal renal function. J Renal Nutr.2004; 14: 226–32.
2.
LaburteC., GrossmanR., Abi-RachedJ.Efficacy and safety of oral cyclosporine A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol.1994; 130: 366–75.
3.
MaginaS., SantosJ., CoroasA.Salt sensitivity of blood pressure in patients with psoriasis on ciclosporin therapy. Br J Dermatol.2005; 152: 773–6.
4.
PennI.The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol.1998; 20: 343–55.
5.
PennI.Post-transplant malignancy: the role of immunosuppression. Drug Safety.2000; 23: 101–13.
6.
RyffelB., MihatschM.J., FisherG.L.Immunosuppression and cancer: the ciclosporin case. Drug Chem Toxicol.1992; 15: 95–115.
7.
GilbertS.C., EmmettM., MenterA.Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function. J Am Acad Dermatol.1989; 21: 470–4.
8.
KorstanjeM.J., BiloH.J., StoofT.J.Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporine therapy. Br J Dermatol.1992; 127: 501–4.
9.
LoweN.J., WiederJ.M., RosenbachA.Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol.1996; 35: 710–9.
10.
MessanaJ.M., JohnsonK.J., MihatschM.J.Renal structure and function effects after low dose cyclosporine in psoriasis patients: a preliminary report. Clin Nephrol.1995; 43: 150–3.
11.
PeiY., ScholeyJ.W., KatzA.Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. Am J Kidney Dis.1994; 23: 528–36.
12.
SvarstadE., HellandS., MorkenT.Renal effects of maintenance low-dose cyclosporine A treatment in psoriasis. Nephrol Dial Transplant.1994; 9: 1462–7.
13.
YoungE.W., EllisC.N., MessanaJ.M.A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int.1994; 46: 1216–22.
14.
ZachariaeH., KragballeK., HansenH.E.Renal biopsy findings in long-term cyclosporine treatment of psoriasis. Br J Dermatol.1997; 136: 531–5.
15.
ZachariaeH., HansenH.E., KragballeK.Morphologic renal changes during cyclosporine treatment of psoriasis: studies on pretreatment and posttreatment kidney biopsy specimens. J Am Acad Dermatol.1992; 26: 415–9.
16.
PowlesA.V., HardmanC.M., PorterW.M.Renal function after 10 years' treatment with cyclosporine for psoriasis. Br J Dermatol.1998; 138: 443–9.
17.
Berth-JonesJ., HendersonC.A., MunroC.S.Treatment of psoriasis with intermittent short course cyclosporine (Neoral): a multicentre study. Br J Dermatol.1997; 136: 527–30.
18.
FeutrenG., AbeywickramaK., FriendD.Renal function and blood pressure in psoriatic patients treated with cyclosporine A. Br J Dermatol.1990; 122(36)(suppl): 57–69.
19.
GrossmanR.M., ChevretS., Abi-RachedJ.Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol.1996; 132: 623–9.
20.
HoV.C., GriffithsC.E., AlbrechtG.Intermittent short courses of cyclosporine (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol.1999; 141: 283–91.
21.
HoV.C., GriffithsC.E., Berth-JonesJ.Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol.2001; 44: 643–51.
22.
MrowietzU., FarberL., Henneicke-von ZepelinH.H.Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study. J Am Acad Dermatol.1995; 33: 470–5.
23.
WatabeH., SomaY., ObaraW.Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine. Acta Derm Venereol.2006; 86: 184–5.
24.
MaheE., DescampsV., GrossinM.CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol.2003; 149: 170–3.
25.
CorazzaM., ZampinoM.R., MontanariA.Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology.2003; 206: 330–3.
26.
ZackheimH.S., KooJ., LeBoitP.E.Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine. J Am Acad Dermatol.2002; 47: 155–7.
27.
PielopJ.A., JonesD., DuvicM.Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. Int J Dermatol.2001; 40: 505–11.
28.
CliffS., PettengellR., GhargeS.B-cell lymphoma developing in a patient on cyclosporine for recalcitrant psoriasis. Br J Dermatol.1999; 140: 763–5.
29.
KooJ.Y., KadonagaJ.N., WintroubB.V.The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol.1992; 26: 836–40.
30.
JaberK., HammamiH., YoussefS.[Non-Hodgkin's lymphoma and pustular psoriasis: a case report]. Lymphome malin non hodgkinien et psoriasis pustuleux: a propos d'un cas. Rev Med Intern.2009; 30: 717–9.
31.
BagotM., WechslerJ., PerrusselM.[Pseudolymphoma induced by cyclosporin]. Pseudolymphome induit par la ciclosporine. Ann Dermatol Venereol.1989; 116: 894–6.
32.
VakevaL., ReitamoS., PukkalaE.Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol.2008; 88: 117–20.
33.
PaulC., HornigF.Risk of malignancy associated with cyclosporine use in psoriasis. Dermatology.1999; 198: 320–1.
34.
PaulC.F., HoV.C., McGeownC.Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol.2003; 120: 211–6.
35.
MarcilI., SternR.S.Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet.2001; 358: 1042–5.
36.
KirbyB., RogersS.Gingival hyperplasia in psoriasis patients treated with cyclosporin. Clin Exp Dermatol.2000; 25: 97–8.
37.
NakayamaJ., KogaT., FurueM.Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporine A-induced hypertension in patients with psoriasis. Eur J Dermatol.1998; 8: 563–8.
38.
MerawS.J., SheridanP.J.Medically induced gingival hyperplasia. Mayo Clin Proc.1998; 73: 1196–9.
39.
SantiE., BralM.Effect of treatment on cyclosporine- and nifedipine-induced gingival enlargement: clinical and histologic results. Int J Periodontics Restorative Dent.1998; 18: 80–5.
40.
KruppP., MonkaC.Side-effect profile of cyclosporine A in patients treated for psoriasis. Br J Dermatol.1990; 122(36)(suppl): 47–56.
41.
Garcia-BustinduyM., EscodaM., GuimeraF.J.Safety of long-term treatment with cyclosporine A in resistant chronic plaque psoriasis: a retrospective case series. J Eur Acad Dermatol Venereol.2004; 18: 169–72.
42.
MarsikC., EndlerG., GulesserianT.Classification of chronic kidney disease by estimated glomerular filtration rate. Eur J Clin Invest.2008; 38: 253–9.
43.
CoreshJ., AugusteP.Reliability of GFR formulas based on serum creatinine, with special reference to the MDRD Study equation. Scand J Clin Lab Invest Suppl.2008; 241: 30–8.
44.
CurtisJ.J.Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep.2002; 4: 377–80.
45.
GelfandJ.M., ShinD.B., NeimannA.L.The risk of lymphoma in patients with psoriasis. J Invest Dermatol.2006; 126: 2194–2201.
46.
MargolisD., BilkerW., HennessyS.The risk of malignancy associated with psoriasis. Arch Dermatol.2001; 137: 778–83.
47.
GelfandJ.M., BerlinJ., Van VoorheesA.Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol.2003; 139: 1425–9.
48.
OtleyC.C., PittelkowM.R.Skin cancer in liver transplant recipients. Liver Transplantation.2000; 6: 253–62.
